During the past decade, Central Texas Neurology Consultants conducted 30 clinical trials. In the 10-year time frame, 30 clinical trials started and 11 clinical trials were completed, i.e. on average, 36.7% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 5 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Central Texas Neurology Consultants" #1 sponsor was "Hoffmann-La Roche" with 9 trials, followed by "Celgene" with 4 trials sponsored, "Genzyme, a Sanofi Company" with 4 trials sponsored, "Genentech, Inc." with 3 trials sponsored and "Opexa Therapeutics, Inc." with 3 trials sponsored. Other sponsors include 18 different institutions and companies that sponsored additional 23 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Central Texas Neurology Consultants" #1 collaborator was "Bayer" with 4 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator, "Prothena Biosciences Limited" with 2 trials as a collaborator, "Syneos Health" with 2 trials as a collaborator and "Chugai Pharmaceutical" with 1 trials as a collaborator. Other collaborators include 0 different institutions and companies that were collaborators in the rest 10 trials.

According to Clinical.Site data, the most researched conditions in "Central Texas Neurology Consultants" are "Multiple Sclerosis" (14 trials), "Multiple Sclerosis, Relapsing-Remitting" (10 trials), "Cervical Dystonia" (2 trials), "Idiopathic Hypersomnia" (2 trials) and "Parkinson Disease" (2 trials). Many other conditions were trialed in "Central Texas Neurology Consultants" in a lesser frequency.

Most popular intervention types in "Central Texas Neurology Consultants" are "Drug" (34 trials), "Biological" (11 trials), "Other" (1 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Ocrelizumab" (5 trials), "Interferon beta-1a" (4 trials), "Alemtuzumab 12 mg" (2 trials) and "Alemtuzumab 24 mg" (2 trials). Other intervention names were less common.

The vast majority of trials in "Central Texas Neurology Consultants" are 46 trials for "All" genders.

Currently, there are NaN active trials in "Central Texas Neurology Consultants". undefined are not yet recruiting, 8 are recruiting, 8 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 25 completed trials in Central Texas Neurology Consultants, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Central Texas Neurology Consultants, 1 "Phase 1" clinical trials were conducted, 13 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".